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Myocardial infarctionObjective: The aim of the study was to investigate the association of serum Pentraxin 3 and genotyping with the
risk of developing AMI and its severity.
Patients and methods: Fifty patients admitted to the coronary care unit presented with STEMI (acute ST segment
myocardial infarction) at the Cardiology Department, Menouﬁa University Hospital in the period from October
2014 to April 2015 and another 20 subjects age- and gender-matched were taken as the control group. All pa-
tients and control groups were subjected to the following: Full history taking, complete clinical examination.
ECG and echocardiography and Laboratory investigation including: estimation of lipid proﬁle, urea and creati-
nine, CKMB, troponin I, serum pentraxin 3 and Genotyping of pentraxin 3 A/G SNP (rs2305619).
Results: The patients with myocardial infarction had signiﬁcantly higher levels of pentraxin 3 than the controls.
The cut-off values for PTX3 and troponin I were 4.35 ng/ml and 0.34 μg/l respectively. Pentraxin 3 showed the
highest diagnostic accuracy of coronary artery disease (96%), with sensitivity (96%) and speciﬁcity (95%). The
highest serum pentraxin 3 levels were in the AA mutant homozygous type.
Conclusion: PTX3 is one of the earliest biomarkers for detecting acute coronary syndrome. rs2305619 AA
genotyping of the pentraxin 3 gene might be a candidate risk factor for development of coronary artery disease,
presumably by increased pentraxin 3 levels.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular disease is the leading cause of mortality in many
countries, accounting for 16.7 million deaths each year [1,2]. Coronary
artery disease (CAD) and cerebrovascular disease are themost common
forms of cardiovascular disease, and they have severe consequences
both for the individual person and society. Their underlying pathologi-
cal process is atherosclerosis, a slowly progressing chronic disorder of
large and medium-sized arteries [3].
For many years it was believed that atherosclerosis was merely
passive accumulation of cholesterol in the vesselwall. Today, the picture
is much more complex, with atherosclerosis being thought of as a
chronic inﬂammatory disease [4].
Pentraxins form a superfamily of acute phase proteinswith a distinc-
tive multimeric organization. On the basis of the primary structure of
the composing protomers, pentraxins are divided into two groups:
short and long pentraxins. C-reactive protein (CRP) and serum amyloid
P (SAP) components are typical short pentraxins and they represent the
main acute phase reactants in humans and mice, respectively [5].
Pentraxin 3(PTX3) is the prototypic long pentraxin, a subfamily of, Egypt.
elegy).
. This is an open access article underpentraxins that are characterized by the presence of a long N-terminal
domain, unrelated to other known proteins, associated with a C-
terminal pentraxin-like domain. This last domain is 200 amino acids
long and it contains the conserved 8 amino acid-long pentraxin
signature [6].
In humans, PTX3 plasma levels predict 3-month mortality in
patients with AMI [7] and increased tissue and plasma levels of PTX3
were also found in patients with non-rheumatic aortic valve stenosis,
suggesting a role as a diagnostic and prognostic biomarker [8].
A number of evidences point to PTX3 as a useful marker of vascular
integrity, including the observations that high levels of PTX3 are seen in
the heart and vascular cells in response to inﬂammatory signals and ox-
LDL and the protein is present in atherosclerotic lesions [9].
The aim of this study was to detect if there is an association of
pentraxin 3 genotyping and pentraxin 3 plasma levels with the risk of
developing and severity of AMI in Egyptian patients.
2. Subjects
This studywas conducted on 70 subjects. Theywere categorized into
Group 1 (patients): Composed of ﬁfty patients with an established
diagnosis of STEMI presented to the Cardiology Department, Menouﬁa
University Hospital in the period from October 2014 to April 2015.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and echocardiography. Quantitative evaluation of the severity of
coronary artery stenosis by angiography was according to the standard
criterion recommended by the American Heart Association [10]. Group
2 (control): Included 20 apparently healthy subjects serving as a control
group.
Exclusion criteria include all patients who had acute non-ST
segment elevation myocardial infarction (NSTEMI); valvular heart
disease; heart failure; hepatic or renal dysfunction; evidence of active
infective, or neoplastic conditions; chronic inﬂammatory diseases.
All patients and control groups were subjected to the following: Full
history taking, complete clinical examination, ECG and echocardiogra-
phy and laboratory investigation including: estimation of lipid proﬁle,
urea and creatinine, CKMB, troponin I, serum pentraxin 3 and genotyp-
ing of pentraxin 3 A/G SNP (rs2305619).
A written consent was obtained from each individual and the
protocol was approved by the ethical committee of the Menouﬁa
Faculty of Medicine and follows the Declaration of Helsinki.
3. Methods
5 ml of venous blood was collected from all subjects included in this
study by venipuncture from the cubital vein, and was collected as
follows: 2.5 ml was collected into EDTA containing tubes, for genotyp-
ing of the pentraxin 3 gene. 2.5 ml was collected in another vacutainer
tube (with no additives), centrifuged at 3000 rpm for 10 min then the
serawere separated into several aliquots for colorimetric determination
of serum urea [11] and creatinine [12]. Quantitative determination of
total creatine kinase (CK) and CKMB levels in the serum using a
commercial kit was supplied by Bio System Spain [13]. Determination
of total cholesterol and triacylglycerides (TG) was done using
colorimetric enzymatic method. HDLc was measured by the precipita-
tion of chylomicrons, VLDL, and LDL by adding phosphotungstic acid
and magnesium ions to the samples. Centrifugation leaves only the
HDL in the supernatant, their cholesterol content is determined
enzymatically [14]. LDLcwas calculated if TG b400mg/dl by the formula
of Friedewald et al. [15]. Enzyme linked immunosorbant assay (ELISA)
was used for the quantitative determination of serum troponin I [16]
and pentraxin 3 [17].
3.1. Pentraxin 3 genotyping
Genomic DNA was extracted from whole blood using the Gene JET
Whole Blood Genomic DNA Puriﬁcation Mini Kit (Thermo Scientiﬁc,
Vilnius, Lithuania).
Pentraxin 3 rs2305619 was genotyped using the TaqMan allelic
discrimination assay technique that detects variants of a single nucleic
acid sequence. The presence of two primer/probe pairs in each reaction
allows genotyping of the two possible variants at the SNP site in a target
template sequence. The actual quantity of the target sequence is not
determined. The allelic discrimination assay classiﬁes unknown
samples as follows: [1] Homozygotes (samples with only allele 1 or
allele 2). [2] Heterozygotes (samples with both allele 1 and allele 2).
Using theMaxima Probe qPCRMaster Mix (2×), primers and probes
were purchased from Applied Bio System. According to Sébastien et al.
[18] the forward primer was 5′-CATCCCACTGAGGACCGTAAG-3′, and
the reverse primerwas 5′-GGTGGATATGTAGTCAGGGTTAGC-3′. Probes:
allele G, 5′-FAM CTTTAACTGTTTCTCTGCTAACCCT TBHQ-3′, and allele A,
5′-VIC CCATCCCACTGAGGACCGTAAGTTC-BHQ-3′. The genotyping
reaction mix was prepared by mixing 12.5 μl master mix, 1.25 of the
genotyping assay mix (probe & primers) and 6.25 μl of DNAse-free
water. For each unknown reaction, 5 μl (0.1 μg/μl) of genomic DNA
template was added and for the negative control reaction, 5 μl of
DNAse-free water was added.
The cycling parameters were set as follows: initial denaturation step
at 95 °C for 10min, 40 cycles of denaturation at 94 °C for 15 s, annealing/collection at 50 °C for 60 s, and extension at 72 °C for 2 min, and a ﬁnal
extension step at 72 °C for 3 min using 7500 Real-Time PCR System
(Applied Bio System Co. Ltd., San Francisco Bay Area, USA). Then the
results were analyzed as in Fig. 1. See Figs. 2 and 3
4. Statistical analysis
Student's t-test was used for comparison between groups of quanti-
tative variables. Mann–Whitney test (U) was used as a test of signiﬁ-
cance for comparison between two groups not normally distributed
having quantitative variables. Kruskal–Wallis test was used as a test of
signiﬁcance for comparison betweenmore than two groups not normal-
ly distributed having quantitative variables. Chi-squared test (χ2) was
used to study the association between two qualitative variables. Fisher's
exact test was used for 2 × 2 tables when the expected cell count of
more than 25% of cases was less than 5. Receiver-operating characteris-
tic (ROC) curve was used to determine cutoff points, sensitivity and
speciﬁcity for quantitative variables of interest and 2 × 2 tables were
used for the calculation of PPV, NPV and diagnostic accuracy. Spearman
correlation coefﬁcient test (r-test) is a test of signiﬁcance used to study
the correlation between nonparametric quantitative variables. Correla-
tion coefﬁcient test (r-test) results may be positive (+) correlation or
negative (−) correlation. It is used to quantify the strength of the linear
relationship between two variables. Odds ratio: describes the probabil-
ity that people who are exposed to a certain factor will have a disease
compared to people who are not exposed to the factor and obtained
by regression analysis. P value of N0.05 was considered statistically
insigniﬁcant. P value of ≤0.05 was considered statistically signiﬁcant. P
value of ≤0.001 was considered statistically highly signiﬁcant.
5. Results
There is a signiﬁcant statistical difference between the two studied
groups regarding heart rate and ejection fraction, while non-
signiﬁcant difference as regards other clinical data, medical history,
age and gender (Table 1). See Table 2
There is a signiﬁcant difference among the two studied groups
regarding total cholesterol, triglyceride, LDL, HDL, CK-MB, troponin I
and serum pentraxin 3, while there was non signiﬁcant difference re-
garding blood urea and serum creatinine (Table 3). There is a signiﬁcant
statistical difference as regards pentraxin 3 genotype distribution in
comparing the two studied groups with increased frequency of the AA
and AG genotypes and A allele in the patient group and increased GG
genotype frequency in the control group. The results showed that the
AG genotype of pentraxin 3 increases the risk of coronary artery disease
by 5.14 fold and AA genotype increases the risk by 4.82 fold, while the A
allele increases the same risk by 2.3 fold (Table 4).
The diagnostic accuracy of serum pentraxin 3 in the diagnosis of
coronary artery disease is (96%), with sensitivity (96%), speciﬁcity
(95%), positive predictive value (98%) and negative predictive value
(90%) at the cutoff point of 4.35 IU/ml. The diagnostic accuracy of tropo-
nin I in the diagnosis of coronary artery disease is (80%), with sensitivity
(82%), speciﬁcity (75%), positive predictive value (89%) and negative
predictive value (63%) at the cutoff point of 0.34 IU/ml, while the
diagnostic accuracy of combined serum pentraxin 3 and troponin I in
the diagnosis of coronary artery disease is (82%), with sensitivity
(95%), speciﬁcity (98%), positive predictive value (68%) and negative
predictive value (86%) (Table 5).
There is a signiﬁcant positive relationship between serum pentraxin
3 and age, LAD target vessel, % of occlusion and a signiﬁcant negative re-
lationship between serum pentraxin 3 levels and ejection fraction,
while there is a non-signiﬁcant relationship regarding other parameters
(Table 6).
There is a signiﬁcant positive correlation between serumpentraxin 3
and each of TG, LDL, CK-MB and troponin I, a signiﬁcant negative
Fig. 1.Genotyping result: round blackdots on the right lower region indicate (AA), gray dots on the centre indicate (AG) and blackdots on the left upper region indicate (GG) genotypingof
rs2305619 of pentraxin 3.
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non-signiﬁcant relationship regarding other parameters (Table 7).
There is a signiﬁcant statistical difference between the troponin I
positive and negative cases at the samples taken before and after 2 h,
while there was a non-signiﬁcant statistical difference between the
serum pentraxin 3 positive and negative cases at the samples taken
before and after 2 h (Table 8).
There is a signiﬁcant statistical difference between TC, TG, LDL and
serum pentraxin 3 levels according to pentraxin 3 genotyping in the
patient group, while there is no signiﬁcant statistical difference
regarding other parameters (Table 9).Fig. 2.ROC curve for detection of the best cutoff point of serumpentraxin 3 in cases ofMI. The are
curve (P value b 0.001) at 95% conﬁdence interval = 0.96 to 1.00.Serum pentraxin 3 is the most signiﬁcant independent risk factor
followed by HDL, TG, pentraxin 3 AA genotypes, troponin I and total
cholesterol, while LDL and CH-MB are not independent risk factors
(Table 10).
6. Discussion
Inﬂammation plays a critical role in the development and progres-
sion of coronary heart disease (CHD), and increased local inﬂammation
may induce plaque rupture, which has been acknowledged as the initial
factor in acute coronary syndrome [19].a under the curvewas 0.986. Therewas a highly signiﬁcant difference in the areaunder the
Fig. 3. ROC curve for detection of the best cutoff point of serum troponin I in cases of MI. The area under the curvewas 0.846. Therewas a highly signiﬁcant difference in the area under the
curve (P value b 0.001) at 95% conﬁdence interval = 0.739 to 0.952.
Table 1
Demographic characteristics, medical history and clinical data of the two studied groups.
Demographic
characteristics
Studied groups Test of
signiﬁcance
P
value
Controls
(n = 20)
Cases
(n = 50)
Age (years)
Mean ± SD 54.96 ± 6.61 55.10 ± 8.17 t-test = 0.07 N0.05
Range 42.00–65.00 40.00–66.00
HR (B/M)
Mean ± SD 91.92 ± 15.64 75.55 ± 11.57 4.23 b0.001
Range 50.00–115.00 60.00–100.00
SBP (mm Hg)
Mean ± SD 129.10 ± 18.42 124.50 ± 16.69 0.97 N0.05
Range 100.00–180.00 100.00–160.00
DBP (mm Hg)
Mean ± SD 84.70 ± 11.71 83.50 ± 10.39 0.39 N0.05
Range 60.00–110.00 70.00–100.00
Ejection fraction
Mean ± SD 52.86 ± 6.18 60.00 ± 3.66 5.97 b0.001
Range 40.00–65.00 52.00–65.00
No. % No. %
Sex
Male 33 66.0 12 60.0 χ2 = 0.22 N0.05
Female 17 34.0 8 40.0
Smoking
Positive 20 40.0 8 40.0 0.00 N0.05
Negative 30 60.0 12 60.0
DM
Positive 27 54.0 11 55.0 0.006 N0.05
Negative 23 46.0 9 45.0
HTN
Positive 15 30.0 6 30.0 0.00 N0.05
Negative 35 70.0 14 70.0
Dyslipidemia
Positive 20 40.0 8 40.0 0.00 N0.05
Negative 30 60.0 12 60.0
FH of CAD
Positive 10 20.0 4 20.0 0.00* N0.05
Negative 40 80.0 16 80.0
χ2 = Chi square test. * Fisher's exact test.
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its expression pattern is more tissue speciﬁc, especially in light of the
fact that it is expressed in cells of the atherosclerotic plaque itself, and
reﬂects active atherosclerosis [20].
Pathological study of the human coronary artery showed that
immunoreactivity for PTX3 was quite sparse in lipid-rich lesions in
ﬁbro atheroma and areas with intra-plaque hemorrhage containing
abundant PTX3 [21].
The PTX3 gene encodes for the long pentraxin PTX3, a molecule
involved in the inﬂammatory response and associated with cardio-
and atheroprotective functions. Data obtained in different in vivo
models showed that PTX3 is involved in modulating inﬂammation in
AMI and atherosclerosis [22].
Moreover, it represents a useful diagnostic and prognostic marker in
cardiovascular pathology [9].Table 2
Characteristics of the patient groups regarding angiography, pain sampling intervals and
types of treatments.
Studied parameters No. %
Target vessels
LAD 17 34.0
LCX 7 14.0
RCA 10 20.0
DIAG 9 18.0
RAM 4 8.0
OM 3 6.0
Site of the lesion
Proximal 27 54.0
Middle 18 36.0
Distal 5 10.0
Therapy
Thrombolytics 30 60
PPCI 20 40
% of occlusion
Mean ± SD 89.20 ± 9.76
Range 70.00–100.00
Pain-sampling interval (hours)
Mean ± SD 4.38 ± 1.46
Range 1.30–6.00
LAD: left anterior descending branch; LCX: left circumﬂex branch; DIAG: diagonal branch;
RCA: right coronary artery branch.
Table 3
Statistical comparison of laboratory investigation among the two studied groups.
Laboratory
parameters
Studied groups Test of
signiﬁcance
P
value
Cases (n = 50) Controls (n = 20)
Serum creatinine (mg/dl)
Mean ± SD 0.98 ± 0.21 1.06 ± 0.19 t = 1.51 N0.05
Range 0.65–1.48 0.60–1.35
Blood urea (mg/dl)
Mean ± SD 34.08 ± 15.44 36.74 ± 11.06 U = 1.69 N0.05
Range 18.00–115.00 19.00–66.00
TC (mg/dl)
Mean ± SD 174.53 ± 36.75 154.86 ± 10.97 t = 3.42 b0.001
Range 107.00–264.80 133.50–175.00
TG (mg/dl)
Mean ± SD 133.84 ± 17.83 106.20 ± 10.60 t = 7.98 b0.001
Range 100.00–170.00 92.00–129.00
LDL (mg/dl)
Mean ± SD 107.53 ± 38.57 85.37 ± 11.28 U = 2.74 b0.01
Range 33.34–200.00 65.50–108.60
HDL (mg/dl)
Mean ± SD 38.52 ± 4.94 48.25 ± 3.27 t = 9.61 b0.001
Range 30.00–48.00 42.00–55.00
CK-MB (IU/ml)
Mean ± SD 35.10 ± 14.49 16.35 ± 5.27 U = 5.75 b0.001
Range 12.00–72.00 6.00–28.00
Troponin I (μg/l)
Mean ± SD 0.62 ± 0.28 0.18 ± 0.27 U = 4.56 b0.001
Range 0.02–1.07 0.01–0.62
Serum pentraxin 3 (ng/ml)
Mean ± SD 10.12 ± 3.64 2.52 ± 1.73 U = 6.12 b0.001
Range 3.80–15.90 0.70–6.90
t: t-test; U: Mann–Whitney test.
Table 6
Relationship between serum pentraxin 3 level and clinical data among the studied cases.
Studied
parameters
N Serum pentraxin 3 level
(ng/ml)
Test of
signiﬁcance
P value
Mean ± SD
Age (years) 50 r =−0.46 Spearman's rho 0.001
Sex
Male 33 10.55 ± 3.93 U = 0.97 N0.05
Female 17 9.55 ± 3.00
Smoking
Smoker 20 10.49 ± 4.24 U = 0.47 N0.05
Non-smoker 30 10.02 ± 3.25
DM
Positive 27 10.67 ± 3.47 U = 0.95 N0.05
Negative 23 9.66 ± 3.84
HTN
Positive 15 11.11 ± 4.27 U = 1.17 N0.05
Negative 35 9.82 ± 3.33
Dyslipidemia
Positive 20 10.22 ± 3.55 U = 0.01 N0.05
Negative 30 10.20 ± 3.76
FH of CAD
Positive 10 11.90 ± 3.14 U = 1.64 N0.05
Negative 40 9.79 ± 3.67
HR 50 r = 0.11 Spearman's rho N0.05
SBP 50 r =−0.07 Spearman's rho N0.05
DBP 50 r = 0.11 Spearman's rho N0.05
EF 50 r =−0.56 Spearman's rho b0.001
Target vessel
LAD 17 13.78 ± 1.78 K = 36.95 b0.001*
LCX 7 6.93 ± 1.32
RCA 10 11.36 ± 2.84
Diag 9 7.59 ± 1.68
RAM 4 8.25 ± 1.53
OM 3 4.30 ± 0.56
Site of culprit lesion
Proximal 27 10.22 ± 3.94 K = 0.78 N0.05
Middle 18 9.83 ± 3.71
Distal 5 11.48 ± 0.89
% of occlusion 50 r = 0.66 Spearman's rho 0.001
K=Kruskal-Wallis Test. * Post Hoc test for target vessel show.
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pentraxin 3 level in the susceptibility to AMI and also the possible effect
of the rs2305619 SNPs on serum PTX3 levels.
This study showed that there was a signiﬁcant statistical difference
between patients with myocardial infarction and the control group asTable 4
Comparison between the two studied groups regarding pentraxin 3 genotyping.
Genotyping Studied groups χ2 test P value OR (95% CI)
Cases
(n = 50)
Controls
(n = 20)
No. % No. %
Allele frequency
G 42 42.0 25 62.5
A 58 58.0 15 37.5 4.81 0.03 S 2.30 (1.08–4.89)
Genotype
GG 7 14.0 9 45.0 Reference
AG 28 56.0 7 35.0 6.70 0.009 S 5.14 (1.42–18.67)
AA 15 30.0 4 20.0 4.61 0.03 S 4.82 (1.10–21.19)
Table 5
Clinical performance of serum pentraxin 3 and troponin I in cases with acute ST-segment elev
Cardiac marker Optimal cutoff point Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
Serum pentraxin 3
(ng/ml)
4.35 (ng/ml) 96% (85–99) 95% (73–99
Troponin I
(μg/l)
0.34 (μg/l) 82% (68–91) 75% (73–99
Combined pentraxin & troponin – 82% (68–91) 95% (73–10
95% CI = 95% conﬁdence interval; PPV = positive predictive value.
NPV= negative predictive value; DOR = diagnostic odds ratio.regards lipid proﬁle, CKMB, troponin I and serum pentraxin 3 levels.
This was in agreement with the several studies [23,24,25] which stated
that the coronary artery disease group had signiﬁcantly higher PTX-3
levels than the control group. This can be explained by, PTX-3 binds
and inactivates ﬁbroblast growth factor-2, an angiogenic growth factor
responsible for smooth muscle proliferation in atherosclerosis or may
be part of a protective mechanism in vascular repair [26]. Very high
levels of PTX-3 may indicate a more severe vascular disease state,
explaining its ability to detect increased risks for adverse outcomes [27].
PTX3 is rapidly induced inmouse and ratmodels ofMI and is present
in atherosclerotic lesions, inﬂammatory cytokines rapidly induce high
levels of PTX3 expression in the heart, most prominently in heart
endothelial cells [20]. In vitro, this prototypic long pentraxin is induced
in endothelial cells, smooth muscle cells, and mononuclear phagocytes
by primary inﬂammatory cytokines (IL-1, tumor necrosis factor) and
oxidized LDL [28].ation myocardial infarction.
PPV
(95% CI)
NPV
(95% CI)
Diagnostic accuracy
(95% CI)
DOR
(95% CI)
) 98% (88–99) 90% (68–98) 96% (87–99) 10.29 (2.75–38.46)
) 89% (76–96) 63% (41–80) 80% (68–88) 2.38 (1.40–4.02)
0) 98% (86–100) 68% (48–83) 86% (75–93) 3.04 (1.77–5.21)
Table 7
Correlation between serum pentraxin 3 level and laboratory parameters among the stud-
ied cases (n = 50).
Laboratory parameters Serum pentraxin 3 (ng/ml)
r (correlation coefﬁcient) P value
Serum creatinine (mg/dl) −0.02 N0.05
Blood urea (mg/dl) −0.03 N0.05
TC (mg/dl) 0.14 N0.05
TG (mg/dl) 0.49 b0.001
LDL (mg/dl) 0.55 b0.01
HDL (mg/dl) −0.46 b0.001
CK-MB (IU/ml) 0.51 b0.001
Troponin I (μg/l) 0.61 b0.001
r: Spearman correlation coefﬁcient.
Table 8
Statistical comparison between cases with pain sample interval less than or equal to and
more than 2 h as regards serum pentraxin 3 and troponin I levels.
Cardiac markers Pain sampling interval
among cases (n = 50)
Fisher's exact test P value
≤2 h
(n = 8)
N2 h
(n = 42)
No. % No. %
Serum Pentraxin 3
Positive 8 100 40 95.2
Negative 0 0.0 2 4.8 0.39 N0.05
Troponin I
Positive 4 50.0 37 88.1
Negative 4 50.0 5 11.9 4.28 b0.05
11E.K. El Melegy et al. / Clinical Trials and Regulatory Science in Cardiology 13 (2016) 6–13In this study a signiﬁcant positive correlation of PTX3 concentrations
has been found in association with age, but not with sex. This was in
agreement with previous studies [29,30,31], while the study of Noriaki
et al. [32] found no correlation between serum pentraxin 3 and age.Table 9
Comparison between different genotypes of pentraxin 3 among coronary artery disease patien
Laboratory parameters Genotyping of cases (n = 50)
GG
(n = 7)
AG
(n = 28)
Serum creatinine (mg/dl)
Mean ± SD 1.10 ± 0.22 0.97 ± 0.23
Range 0.80–1.33 0.58–1.48
Blood urea (mg/dl)
Mean ± SD 36.04 ± 11.69 36.61 ± 18.78
Range 20.00–50.00 18.00–115.00
TC (mg/dl)
Mean ± SD 184.83 ± 26.85 161.86 ± 34.71
Range 158.67–220.92 107.00–232.14
TG (mg/dl)
Mean ± SD 134.57 ± 21.99 128.25 ± 15.99
Range 100.00–160.00 100.00–160.00
LDL (mg/dl)
Mean ± SD 92.09 ± 24.78 96.71 ± 36.35
Range 49.80–153.32 33.34–174.34
HDL (mg/dl)
Mean ± SD 39.00 ± 3.56 39.57 ± 5.23
Range 33.00–43.00 30.00–48.00
CK-MB (IU/ml)
Mean ± SD 37.43 ± 15.49 34.75 ± 14.58
Range 21.00–59.00 12.00–72.00
Serum pentraxin 3 (ng/ml)
Mean ± SD 8.54 ± 3.32 9.48 ± 3.46
Range 4.20–12.50 4.50–15.70
Troponin I (μg/l)
Mean ± SD 0.57 ± 0.46 0.35 ± 0.23
Range 0.11–1.07 0.11–0.97The results of this study showed that there was a linear relationship
between PTX3 and, left anterior descending branch (LAD) target vessel
affection and % of occlusion and a signiﬁcant negative relationship
between serum pentraxin 3 levels and ejection fraction.
Our results are matched with Hua et al. (2015) [33] who found that
serum PTX3 was positively correlated with cardiac artery occlusion %.
Also, other studies stated that PTX3 has the potential to be a more
speciﬁc marker for the severity of CAD as measured by the Gensini
score, than CRP [34,35,36].
The superior prognostic value of PTX-3 might result from a higher
speciﬁcity of PTX-3 for localized inﬂammation and damage in the
cardiovascular system [37]. A previous study has shown that PTX3 can
predict 3-month mortality after AMI [7].
In the present study, the diagnostic accuracy of serumpentraxin 3 in
the diagnosis of coronary artery disease is (96%), with sensitivity (96%),
speciﬁcity (95%), positive predictive value (98%) and negative
predictive value (90%) at the cutoff point of 4.35 IU/ml.
These results are in agreementwith several studieswhich found that
sensitivity and speciﬁcity of PTX3 for the diagnosis of ACS appear to be
higher than other cardiac markers. The area under the curve (AUC)
value for PTX3 was 0.920 [18,32]. It also matched with a study showing
that sensitivity and speciﬁcity of PTX3 for the diagnosis of ACS appear to
be higher than those of TnT with a sensitivity 98.5% and 94.4% and
speciﬁcity 92.3% and 86.2 respectively [38].
PTX-3 seems to be amore speciﬁc and sensitivemarker in cardiovas-
cular diseases. Measurement of plasma PTX-3 represents a more
effective means for early risk stratiﬁcation compared to hs-CRP in
patients with myocardial infarction [7] and chronic heart failure [39].
In the present study, serum pentraxin levels show more positive
cases than troponin I with a pain sample interval less than 2 h. So,
PTX-3 may be more valuable and beneﬁcial in diagnosing ACS rather
than other cardiac markers, particularly within the ﬁrst two hours
after the onset of chest pain.
This result also is in agreementwith Peri et al. [29]who stated that in
patients with acute myocardial infarction, PTX3 peaked in plasma
sooner than other markers. The distribution of PTX3 plasma levelsts regarding laboratory investigation.
Kruskal–Wallis test P value
AA
(n = 15)
0.93 ± 0.16 2.69 N0.05
0.56–1.20
28.45 ± 6.84 4.25 N0.05
19.00–40.00
193.37 ± 36.61 6.48 b0.05
138.27–264.80
143.93 ± 15.48 7.24 b0.05
120.00–170.00
130.24 ± 36.55 6.79 b0.05
72.27–200.00
36.33 ± 4.47 3.98 N0.05
30.00–43.00
34.67 ± 14.79 0.05 N0.05
18.00–70.00
12.03 ± 3.93 6.19 b0.05
6.60–15.90
0.32 ± 0.15 0.44 N0.05
0.11–0.55
Table 10
Multivariate analysis of risk factors of coronary artery disease.
Risk factors OR (95% CI) P value
TC (mg/dl) 1.28 (0.89–1.83) b0.05
TG (mg/dl) 3.25 (1.09–9.67) b0.01
LDL (mg/dl) 0.76 (0.46–1.26) N0.05
HDL (mg/dl) 3.63 (1.76–7.45) b0.01
CK-MB (IU/ml) 0.66 (0.43–1.0) N0.05
Troponin I (μg/l) 1.55 (0.95–2.51) b0.05
Serum pentraxin 3 (ng/ml) 5.61 (2.53–11.87) b0.01
Genotype (AA vs. [AG + GG]) 2.02 (1.22–3.35) b0.01
Odds ratio (OR) at 95% conﬁdence intervals (CI).
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the AA genotype at the rs2305619 SNP had the higher amount of
PTX3 in the blood compared to the AG and GG carriers, while GG
genotyping is associated with the lower value of plasma PTX3.
These results are matched with the study of Barbati et al. [24] who
stated that carriers for AA rs2305619 (vs.AG and GG genotypes) had
higher PTX3 levels, while GG genotyping has been previously associated
with a protective effect against pulmonary tuberculosis inWest Africans
[40] and Pseudomonas aeruginosa colonization in Italian cystic ﬁbrosis
patients [41].
Themechanismbywhich PTX3 SNPs affect PTX3 plasma levels is still
to be clariﬁed but possibly the rs2305619 genetic variant is in linkage
with a regulatory region, perhaps the PTX3 promoter. So, it could affect
the binding of a transcription factor to its consensus binding site,
modifying the PTX3 expression level. It cannot be completely ruled
out that PTX3 SNPs are related to high plasma levels of a functionally
less active protein [24].
This study showed that serum pentraxin 3 is themost signiﬁcant in-
dependent risk factor for coronary artery disease. This matched with
Norata et al. [9] who found that when pentraxin 3 was measured with
established markers including CRP, NT-proBNP and troponin-T, it
emerged as the only independent predictor of three-month mortality.7. Conclusion
It can be concluded that diagnostic sensitivity and speciﬁcity of PTX3
for ACS, in the early stage, appear to be superior to those of troponin I,
thus, indicating that PTX3 is one of the useful biomarkers for detecting
ACS, alone or in combination with other biomarkers including Tn I.
PTX3 is likely to be an earlier systemic inﬂammatory marker than
troponin I.
rs2305619 in the pentraxin3 genemight be a candidate risk factor for
the development of coronary artery disease, presumably by increasing
pentraxin 3 levels. Individuals carrying the A/A or AG genotype and
the A allele of pentraxin3 rs2305619 have an increased risk of
developing coronary artery disease, whereas individuals carrying the
GG genotype and the G allele have a protective effect for developing
coronary artery disease. Further study is needed to investigate the larger
sample size and the role of other SNPs of the pentraxin 3 gene in
coronary artery disease.Disclosures
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